<DOC>
	<DOCNO>NCT01302808</DOCNO>
	<brief_summary>RATIONALE : Romidepsin erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase I/II trial study side effect best dose romidepsin give together erlotinib hydrochloride see well work treat patient stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Romidepsin Erlotinib Hydrochloride Treating Patients With Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To characterize toxicity determine maximum-tolerated dose ( MTD ) erlotinib hydrochloride plus romidepsin . ( Phase I ) - To obtain preliminary data regard efficacy , include response rate progression-free survival . ( Phase II ) Secondary - To characterize pharmacokinetic profile romidepsin combination erlotinib hydrochloride . - To evaluate impact erlotinib hydrochloride biologic activity romidepsin analyze peripheral blood mononuclear cell ( PBMC ) histone acetylation status histone acetylase activity . ( Exploratory ) - To evaluate effect romidepsin erlotinib hydrochloride component EGFR-signaling pathway skin biopsy , particularly downstream mediator MAPK . ( Exploratory ) OUTLINE : This dose-escalation study romidepsin follow phase II study . Patients receive romidepsin IV day 1 , 8 , 15 erlotinib hydrochloride orally ( PO ) daily begin day 3 course 1 day 1-28 subsequent course . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo blood sample collection baseline periodically study pharmacokinetic study . Additional sample peripheral blood mononuclear cell skin biopsy may also collect correlative study . After completion study therapy , patient follow 30 day . PROJECTED ACCRUAL : A total 39 patient ( 15 patient phase I 24 patient phase II ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm locally advanced metastatic ( stage IIIB pleural effusion stage IV ) nonsmall cell lung cancer ( NSCLC ) , include follow cell type : Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma Large cell carcinoma Large cell neuroendocrine Carcinoma otherwise specify Measurable disease define RECIST Clinically stable brain metastasis permit PATIENT CHARACTERISTICS : ECOG performance status 01 Serum potassium ≥ 3.8 mmol/L magnesium ≥ 2.0 mg/dL Electrolyte abnormality may correct supplementation Hemoglobin ≥ 10 g/dL ( transfusion and/or erythropoietinstimulating agent permit ) ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2.0 time ULN ( &lt; 3 time ULN presence demonstrable liver metastasis ) Serum creatinine &lt; 2.0 time ULN Not pregnant nursing Negative urine serum pregnancy test Women childbearing potential men must use effective barrier method contraception ( e.g. , intrauterine contraception device [ IUCD ] , doublebarrier method use condom , diaphragm plus spermicide ) treatment period least 1 month thereafter No known cardiac abnormality , include follow : Congenital long QT syndrome QTc interval &gt; 480 msec Myocardial infarction within 12 month prior study entry Other significant electrocardiogram ( ECG ) abnormality , include type II second thirddegree atrioventricular ( AV ) block , bradycardia ( ventricular rate &lt; 50 beats/min ) History coronary artery disease ( CAD ) ( e.g. , angina Canadian class IIIV ) For patient doubt , stressimaging study perform abnormal , angiography also perform define whether CAD present An ECG record screen show significant ST depression ( ST depression ≥ 2 mm , measure isoelectric line ST segment point 60 msec end QRS complex ) NYHA class II IV congestive heart failure ( CHF ) , and/or ejection fraction ( EF ) &lt; 40 % MUGA scan &lt; 50 % ECG and/or MRI Known history sustain ventricular tachycardia ( VT ) , ventricular fibrillation ( VF ) , Torsades de Pointes , cardiac arrest , unless currently address automatic implantable cardiac defibrillator ( AICD ) Hypertrophic cardiomyopathy restrictive cardiomyopathy prior treatment cause Uncontrolled hypertension define blood pressure ≥ 160/95 mm Hg Any cardiac arrhythmia require antiarrhythmia medication No clinically significant active systemic , pulmonary , pericardial infection , include know HIV infection hepatitis B C No significant medical psychiatric condition might prevent patient comply study procedure PRIOR CONCURRENT THERAPY : At least 3 week since prior erlotinib hydrochloride ( phase I ) At least 3 week since prior anticancer therapy , discretion investigator , may treatmentnaive ( phase I ) At least 1 2 prior chemotherapy regimen advance NSCLC ( phase II ) At least 3 week since prior chemotherapy NSCLC At least 2 week since prior major surgery radiation therapy No prior erlotinib hydrochloride ( phase II ) No prior romidepsin No concurrent anticancer therapy No prior concurrent investigational agent within 4 week prior study entry No concurrent drug may cause prolongation QTc interval No concurrent CYP3A4 inhibitors No concurrent warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>malignant pleural effusion</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>